Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
SGLT2 inhibitors are a novel class of glucose lowering drugs that act in the kidney by
inhibiting SGLT2-mediated glucose reabsorption in the proximal tubule. The resulting increase
in urinary glucose excretion leads to a reduction in plasma glucose levels. This is
accompanied by reduction of total body weight due to urinary energy loss. In addition,
glucose dependent osmotic diuresis contributes to blood pressure lowering effects of SGLT2
inhibition.
Aim of the trial is to assess hemodynamic changes by empagliflozin, identify new
empagliflozin dependent metabolic regulators and evaluate empagliflozin dependent effects on
cardiac function.